EBMT 2025 | The treatment of R/R large B-cell lymphoma in the second-line setting in the UK

So currently in the UK, within NHS England, we’re lucky to have commissioning or reimbursement for two CD19 CAR T-cell products. We’ve had access to axi-cel for a number of years and more recently we’ve seen NICE approval to recommend routine commissioning for liso-cel in the same setting. So both CD19 CAR-T products are approved and commissioned for the very similar groups of patients. Patients who are refractory to first-line treatment or relapse within 12 months following the end of therapy. But importantly, both groups of patients have to be deemed to be fit enough to have autologous stem cell transplant. That’s in line with the license for axi-cel. The license for liso-cel is broader, but we don’t yet have commissioning for the important group of patients who are not fit enough for autologous transplant, and I think this is a group of patients that really is an unmet need. And looking ahead, we have the potential to get access to a CD20-bispecific antibody therapy, so glofitamab in combination with GemOX that’s soon to be licensed across the FDA, the EMA, hopefully the MHRA in the UK later this year, but for specifically that group, so the group that relapse, need second-line therapy, but are not auto-fit and yet need a novel therapy such as a bispecific antibody. So we really look forward to these novel therapies reaching those groups of patients later in the year.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.